Actinium Pharmaceuticals (ATNM) Life Sciences Investor Forum summary

Strategic pipeline overview

• Focus on targeted radiotherapy for blood cancers, solid tumors, and conditioning for cell/gene therapy, supported by over 230 patents and proprietary Actinium-225 manufacturing technology.

• Lead program Actimab-A advancing to phase II-III trials for AML, with additional studies in solid tumors and combinations with PD-1 inhibitors like KEYTRUDA and OPDIVO.

• Iomab-ACT program initiated in CAR-T and sickle cell disease settings, with trials at UT Southwestern and Columbia University.

• New solid tumor candidate ATNM-400 targets prostate cancer, showing higher potency than PLUVICTO in preclinical models and efficacy in PLUVICTO-resistant tumors.

• In-house R&D and manufacturing capabilities enable expansion into new indications and support future clinical trials.

Clinical and preclinical data highlights

• Actimab-A plus CLAG-M in relapsed/refractory AML showed high response rates (>50%) and deep remissions, including MRD negativity, even in high-risk groups.

• Median overall survival reached 18 months in certain subgroups, with 24 months for those proceeding to bone marrow transplant.

• Actimab-A is mutation agnostic and targets CD33, expressed across AML patients, supporting its potential as a backbone therapy.

• ATNM-400 demonstrated selective tumor uptake, minimal normal tissue exposure, and efficacy in PLUVICTO-resistant models.

• Iomab-ACT pilot study showed low toxicity and complete responses in heavily pretreated leukemia/lymphoma patients, supporting ongoing trials.

Market opportunities and partnerships

• Pipeline addresses large markets: AML, solid tumors, prostate cancer, CAR-T, and sickle cell disease, with potential patient populations exceeding several hundred thousand.

• Actimab-A being studied in combination with PD-1 inhibitors for head and neck and non-small cell lung cancer, targeting resistance mechanisms via MDSC depletion.

• Iomab-ACT targets the rapidly growing cell and gene therapy market, forecasted to reach 100,000 patients by 2030.

• Actinium-225 manufacturing technology offers cost-effective, high-purity isotope production, with potential for external partnerships.

• Actively seeking partnerships for late-stage assets, including Actimab-A and Iomab-B, to accelerate development and commercialization.